Date: 2014-09-01
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the study
Company: Servier (France) Xention (UK)
Product: XEN-D0103
Action
mechanism: XEN-D0103 blocks the atrial specific Kv1.5 potassium channel in the heart and is one of the first such selective drugs to reach the clinic.
Disease: atrial fibrillation
Therapeutic area: Cardiovascular diseases
Country: UK
Trial
details: The XAPAF study is being managed by Xention and is designed to assess the efficacy and safety of XEN-D0103 in patients with paroxysmal atrial fibrillation. The design is a double-blind, randomized, placebo-controlled, crossover trial in a total of twenty patients suffering from paroxysmal atrial fibrillation who also have implanted pacemakers, enabling continuous beat-to-beat monitoring of drug efficacy.
Latest
news: * On September 1, 2014, Xention, a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating anti-arrhythmic drugs, announced that the phase 2 development of its lead atrial fibrillation programme XEN-D0103 is underway. In 2013, Xention entered into an agreement with Servier for the development and commercialisation of XEN-D0103. The joint programme of clinical development for XEN-D0103 includes two phase 2 clinical studies aimed at demonstrating the efficacy of the compound in atrial fibrillation. The first of the planned Phase 2 studies (the \'XAPAF\' study) is being managed by Xention and is being undertaken at Eastbourne General Hospital with Dr Neil Sulke as Principal Investigator.
